title: [Clinical and histological study of lupoid cutaneous leishmaniasis (16 cases)].
abstract: BACKGROUND
  Zoonotic cutaneous leishmaniasis (CL) is characterised by a major clinical polymorphism, especially the lupoid type. The aim of our study was to precise the anatomic and clinical particularities of this clinical form of CL.
  
  
  METHODS
  The present work was a prospective 1-year study. In all patients, the epidemiologic and clinical characteristics were identified, together with those regarding disease progression. Standard cutaneous biopsies were carried out for all study patients.
  
  
  RESULTS
  The lupoid form was observed in 15% of the patients. It was clinically characterised by a lupoid aspect with papular and squamous placard surrounded by a satellite papule, a short duration of disease progression (28 months in average) and a preferential localisation at the level of the face and the elbow, statistically proven. At the histological level, epidermic hyperplasia was found in 93.8% of the cases; an inflammatory polymorphic dermic infiltrate consisting of lymphocytes and plasmocytes was found in all patients; granulomas were noted in 50% of the cases, and isolated epitheloid cells were observed in the derm of 3 patients. Amastigotes were rarely observed.
  
  
  CONCLUSIONS
  In our series, the lupoid form was characterised with a short and non chronic evolution and two preferential sites for the affection: the face and the elbow. At the histological level, the lupoid type of CL appeared characterized by a high frequency of granuloma, usually organized, and rare amastigotes. However, the histology of authentic lupoid forms can be non granolomatosic.
authors.affiliation: Service de dermatologie et de vénéréologie, CHU Hédi Chaker, Sfax, Tunisie. masmoudiabd@yahoo.fr
authors.forename: Abderrahmen
authors.initials: A
authors.lastname: Masmoudi
authors.forename: Sonia
authors.initials: S
authors.lastname: Boudaya
authors.forename: Narjes
authors.initials: N
authors.lastname: Ayadi
authors.forename: Samir
authors.initials: S
authors.lastname: Bouassida
authors.forename: Abdelmajid
authors.initials: A
authors.lastname: Khabir
authors.forename: Taha Jalel
authors.initials: TJ
authors.lastname: Meziou
authors.forename: Feryel
authors.initials: F
authors.lastname: Akrout
authors.forename: Tahia
authors.initials: T
authors.lastname: Sallemi
authors.forename: Hamida
authors.initials: H
authors.lastname: Turki
authors.forename: Abdelmajid
authors.initials: A
authors.lastname: Zahaf
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000965:Antimony / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D001706:Biopsy; D002648:Child; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016773:Leishmaniasis, Cutaneous / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D008795:Metronidazole / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D011446:Prospective Studies; D012867:Skin / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome